Update on tizanidine for muscle spasticity and emerging indications

Bibliography

• Nance PW. Alpha adrenergic and serotonergic agents in the treatment of spastic hypertonia. Phys Med Rehabil Clin N Am 2001;12(4):889-905
   PubMedGoogle Scholar
• Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev 2000;(2):CD001131
   PubMedGoogle Scholar
• Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997;53(3):435-52
   PubMed Web of Science ®Google Scholar
• Nance PW, Sheremata WA, Lynch SG, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997;54(6):731-6
   PubMed Web of Science ®Google Scholar
• Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler 2002;8(4):319-29
   PubMed Web of Science ®Google Scholar
• Nance PW, Bugaresti J, Shellenberger K, et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology 1994;44(11 Suppl 9):S44-51; discussion S-2
   PubMed Web of Science ®Google Scholar
• Gelber DA, Good DC, Dromerick A, et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke 2001;32(8):1841-6
   PubMed Web of Science ®Google Scholar
• Eyssette M, Rohmer F, Serratrice G, et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 1988;10(10):699-708
   PubMed Web of Science ®Google Scholar
• Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 1998;15(4):241-51
   PubMed Web of Science ®Google Scholar
• Lataste X, Emre M, Davis C, Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology 1994;44(11 Suppl 9):S53-9
   PubMed Web of Science ®Google Scholar
• Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004;28(2):140-75
   PubMed Web of Science ®Google Scholar
• Smith H, Elliott J. Alpha(2) receptors and agonists in pain management. Curr Opin Anaesthesiol 2001;14(5):513-8
   PubMedGoogle Scholar
• Malanga GA, Gwynn MW, Smith R, Miller D. Tizanidine is effective in the treatment of myofascial pain syndrome. Pain Physician 2002;5(4):422-32
   PubMedGoogle Scholar
• Manfredini D, Romagnoli M, Cantini E, Bosco M. Efficacy of tizanidine hydrochloride in the treatment of myofascial face pain. Minerva Med 2004;95(2):165-71
   PubMedGoogle Scholar
• Semenchuk MR, Sherman S. Effectiveness of tizanidine in neuropathic pain: an open-label study. J Pain 2000;1(4):285-92
   PubMed Web of Science ®Google Scholar
• Saper JR, Lake AE 3rd, Cantrell DT, et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002;42(6):470-82
   PubMed Web of Science ®Google Scholar
• Berry H, Hutchinson DR. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. J Int Med Res 1988;16(2):75-82
   PubMed Web of Science ®Google Scholar
• Gorska J. Effects of back pain treatment with tizanidine. Ortop Traumatol Rehabil 2005;7(3):306-9
   PubMedGoogle Scholar
• Borg-Stein J, Simons DG. Focused review: myofascial pain. Arch Phys Med Rehabil 2002;83(3 Suppl 1):S40-7, S8-9
   PubMed Web of Science ®Google Scholar
• Littlejohn G. Regional pain syndrome: clinical characteristics, mechanisms and management. Nat Clin Pract Rheumatol 2007;3(9):504-11
   PubMedGoogle Scholar
• Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology 1994;44(11 Suppl 9):S6-10; discussion S-1
   PubMed Web of Science ®Google Scholar
• Mense S. Descending antinociception and fibromyalgia. Z Rheumatol 1998;57(Suppl 2):23-6
   PubMed Web of Science ®Google Scholar
• Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004;10(5):589-95
   PubMed Web of Science ®Google Scholar
• Naugle R. Epidemiology of brain injury. In: Bigler E, editor, Traumatic brain injury: mechanisms of damage, assessment, interventions and outcomes. Austin, TX: Pro Ed, Inc; 1990. p. 69-103
   Google Scholar
• Sommerfeld DK, Eek EU, Svensson AK, et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004;35(1):134-9
   PubMed Web of Science ®Google Scholar
• Watkins CL, Leathley MJ, Gregson JM, et al. Prevalence of spasticity post stroke. Clin Rehabil 2002;16(5):515-22
   PubMed Web of Science ®Google Scholar
• Imamura ST, Fischer AA, Imamura M. Pain management using myofascial approach when other treatment failed. Phys Med Rehabil Clin North Am 1997;8(1):179-96
   Google Scholar
• Lavelle ED, Lavelle W, Smith HS. Myofascial trigger points. Med Clin North Am 2007;91(2):229-39
   PubMed Web of Science ®Google Scholar
• A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology 1994;44(11 Suppl 9):S70-8
   Google Scholar
• Therapeutics A. Zanaflex package insert. Hawthorne, NY; 2006
   Google Scholar
• Catecholamines: bridging basic science with clinical medicine. San Diego: Academic; 1998
   Google Scholar
• Bylund DB, Eikenberg DC, Hieble JP, et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994;46(2):121-36
   PubMed Web of Science ®Google Scholar
• Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Ann Rev Pharmacol Toxicol 2003;43:381-411
   PubMed Web of Science ®Google Scholar
• Langer SZ. 25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Trends Pharmacol Sci 1997;18(3):95-9
   PubMed Web of Science ®Google Scholar
• Starke K, Gothert M, Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 1989;69(3):864-989
   PubMed Web of Science ®Google Scholar
• Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999;402(6758):181-4
   PubMed Web of Science ®Google Scholar
• Davies J. Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiodazole (DS103-282). Br J Pharmacol 1982;76(3):473-81
   PubMed Web of Science ®Google Scholar
• Ono H, Matsumoto K, Kato K, et al. Effects of tizanidine, a centrally acting muscle relaxant, on motor systems. Gen Pharmacol 1986;17(2):137-42
   PubMedGoogle Scholar
• Honda M, Sekiguchi Y, Sato N, Ono H. Involvement of imidazoline receptors in the centrally acting muscle-relaxant effects of tizanidine. Eur J Pharmacol 2002;445(3):187-93
   PubMed Web of Science ®Google Scholar
• Kino Y, Tanabe M, Honda M, Ono H. Involvement of supraspinal imidazoline receptors and descending monoaminergic pathways in tizanidine-induced inhibition of rat spinal reflexes. J Pharmacol Sci 2005;99(1):52-60
   PubMed Web of Science ®Google Scholar
• Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 2002;283(2):R287-95
   PubMed Web of Science ®Google Scholar
• Yaksh TL. Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing. Pharmacol Biochem Behav 1985;22(5):845-58
   PubMed Web of Science ®Google Scholar
• Stone LS, MacMillan LB, Kitto KF, et al. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J Neurosci 1997;17(18):7157-65
   PubMed Web of Science ®Google Scholar
• Sullivan AF, Dashwood MR, Dickenson AH. Alpha 2-adrenoceptor modulation of nociception in rat spinal cord: location, effects and interactions with morphine. Eur J Pharmacol 1987;138(2):169-77
   PubMed Web of Science ®Google Scholar
• Davies J, Quinlan JE. Selective inhibition of responses of feline dorsal horn neurones to noxious cutaneous stimuli by tizanidine (DS103-282) and noradrenaline: involvement of alpha 2-adrenoceptors. Neuroscience 1985;16(3):673-82
   PubMed Web of Science ®Google Scholar
• Shah J, Wesnes KA, Kovelesky RA, Henney HR 3rd. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. Clin Ther 2006;28(9):1308-17
   PubMed Web of Science ®Google Scholar
• Henney HR 3rd, Shah J. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. Clin Ther 2007;29(4):661-9
   PubMed Web of Science ®Google Scholar
• Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 2004;57(3):349-53
   PubMed Web of Science ®Google Scholar
• Granfors MT, Backman JT, Neuvonen M, et al. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 2004;75(4):331-41
   PubMed Web of Science ®Google Scholar
• Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004;76(6):598-606
   PubMed Web of Science ®Google Scholar
• Momo K, Doki K, Hosono H, et al. Drug interaction of tizanidine and fluvoxamine. Clin Pharmacol Ther 2004;76(5):509-10
   PubMed Web of Science ®Google Scholar
• Momo K, Homma M, Kohda Y, et al. Drug interaction of tizanidine and ciprofloxacin: case report. Clin Pharmacol Ther 2006;80(6):717-9
   PubMed Web of Science ®Google Scholar
• Smith C, Birnbaum G, Carter JL, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994;44(11 Suppl 9):S34-42; discussion S-3
   Web of Science ®Google Scholar
• Bass B, Weinshenker B, Rice GP, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988;15(1):15-9
   PubMed Web of Science ®Google Scholar
• Hirata K, Koyama N, Minami T. The effects of clonidine and tizanidine on responses of nociceptive neurons in nucleus ventralis posterolateralis of the cat thalamus. Anesth Analg 1995;81(2):259-64
   PubMed Web of Science ®Google Scholar
• McCarthy RJ, Kroin JS, Lubenow TR, et al. Effect of intrathecal tizanidine on antinociception and blood pressure in the rat. Pain 1990;40(3):333-8
   PubMed Web of Science ®Google Scholar
• Leiphart JW, Dills CV, Levy RM. Alpha2-adrenergic receptor subtype specificity of intrathecally administered tizanidine used for analgesia for neuropathic pain. J Neurosurg 2004;101(4):641-7
   PubMed Web of Science ®Google Scholar
• Gold MS, Dastmalchi S, Levine JD. Alpha 2-adrenergic receptor subtypes in rat dorsal root and superior cervical ganglion neurons. Pain 1997;69(1-2):179-90
   PubMed Web of Science ®Google Scholar
• Ongioco RR, Richardson CD, Rudner XL, et al. Alpha2-adrenergic receptors in human dorsal root ganglia: predominance of alpha2b and alpha2c subtype mRNAs. Anesthesiology 2000;92(4):968-76
   PubMed Web of Science ®Google Scholar
• He L, Wu B, Zhou M. Non-antiepileptic drugs for trigeminal neuralgia (review). Cochrane Database Syst Rev 2006;3:CD004029
   Google Scholar
• Spiller HA, Bosse GM, Adamson LA. Retrospective review of Tizanidine (Zanaflex) overdose. J Toxicol Clin Toxicol 2004;42(5):593-6
   PubMed Web of Science ®Google Scholar
• Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994;44(11 Suppl 9):S60-8; discussion S8-9
   PubMedGoogle Scholar
• de Graaf EM, Oosterveld M, Tjabbes T, Stricker BH. A case of tizanidine-induced hepatic injury. J Hepatol 1996;25(5):772-3
   PubMed Web of Science ®Google Scholar
• Sklerov JH, Cox DE, Moore KA, Levine B, Fowler D. Tizanidine distribution in a postmortem case. J Anal Toxicol 2006;30(5):331-4
   PubMed Web of Science ®Google Scholar
• Therapeutics A. Updated safety information: Contraindications to the use of tizanidine. Hawthorne, NY; 2007
   Google Scholar
• Backman JT, Granfors MT, Neuvonen PJ. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 2006;62(6):451-61
   PubMed Web of Science ®Google Scholar
• Backman JT, Karjalainen MJ, Neuvonen M, et al. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 2006;62(3):345-57
   PubMed Web of Science ®Google Scholar
• Backman JT, Schroder MT, Neuvonen PJ. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol 2007
   Google Scholar
• Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 2005;78(4):400-11
   PubMed Web of Science ®Google Scholar